Figure 4
From: Network meta-analysis of survival data with fractional polynomials
Estimation of hazard ratio over time for gefitinib versus docetaxel as obtained with mixed treatment comparison model (4 gefitinib-docetaxel studies, 1 BSC-docetaxel study, 1 gefitinib-BSC study) is associated with less uncertainty than obtained with a meta-analysis model (4 Gefitinib-Docetaxel studies).